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Abstract
Background: The mechanisms related to cognitive impairment in older persons with Type 2 diabetes (DM) remains unclear.
We tested if adiposity parameters and body fat distribution could predict cognitive decline in older persons with DM vs.
normal glucose tolerance (NGT).
Methodology: 693 older persons with no dementia were enrolled: 253 with DM in good metabolic control; 440 with NGT
(age range:65–85 years). Longitudinal study comparing DM and NGT individuals according to the association of baseline
adiposity parameters (body mass index (BMI), waist-hip-ratio (WHR), waist circumference (WC) and total body fat mass) to
cognitive change (Mini Mental State Examination (MMSE), a composite score of executive and attention functioning (CCS)
over time.
Findings: At baseline, in DM participants, MMSE correlated with WHR (b=20.240; p=0.043), WC (b=20.264; p=0.041)
while CCS correlated with WHR (b=20.238; p=0.041), WC (b=20.326; p=0.013) after adjusting for confounders. In NGT
subjects, no significant correlations were found among any adiposity parameters and MMSE, while CCS was associated with
WHR (b=20.194; p=0.036) and WC (b=20.210; p=0.024). Participants with DM in the 3
rd tertile of total fat mass showed
the greatest decline in cognitive performance compared to those in 1
st tertile (tests for trend: MMSE(p=0.007),
CCS(p=0.003)). Logistic regression models showed that 3
rd vs. 1
st tertile of total fat mass, WHR, and WC predicted an almost
two-fold decline in cognitive function in DM subjects at 2
nd yr (OR 1.68, 95%IC 1.08–3.52).
Conclusions: Total fat mass and central adiposity predict an increased risk for cognitive decline in older person with DM.
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Introduction
Type 2 diabetes mellitus(DM) has been consistently associated
with a higher risk of cognitive decline, especially in older
persons[1]. Such individuals are almost two times more likely to
experience cognitive decline and dementia compared to those with
normal glucose tolerance (NGT)[2]. Such decline maybe in part
due to an array of tissue response from chronic hyperglycemia[3],
postprandial glucose fluctuations[4], advanced glycosylated end-
products[5] and altered insulin action[6]. Even though the
underlying mechanisms explaining the relationship between
diabetes and cognitive decline are still unclear, the presence of
increased visceral fat tissue in older diabetics is no longer
considered an inert bystander, but an active endocrine organ
capable of activating a pro-inflammatory network. Adipose
inflammatory proteins have been indicated in diabetic complica-
tions leading to hypertension, cardiovascular disease and meta-
bolic syndrome[7]. Considering that older diabetics are at a
significantly higher risk of cognitive disability, a further role of
changes in body composition, in particular adipose tissue
distribution on cognitive decline may be hypothesized.
There is a growing body of literature regarding body fat
distribution and cognitive decline in older persons, however
overall findings have been controversial. A recent study showed
that central obesity was not associated with cognitive decline in
older men, while it was associated with a decline in cognitive
function in older women[8], while another study underlined that
both Waist circumference(WC) and Waist-hip-ratio(WHR) were
independent predictors of cognitive function in both older men
and women[9]. There is also recent data demonstrating that
weight gain during middle age is associated an increased risk for
Alzheimer’s disease(AD) in both men and women in old age, while
central obesity predicts an increased risk for AD in women
only[10–11]. Data from the Framingham Heart study showed that
in both obesity and hypertension were independent predictors of
cognitive decline in men, while hypertensive obese men performed
more poorly on cognitive tests than men that were either obese or
hypertensive alone[12]. Considering that fat tissue distribution
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10333seems to play a more detrimental role on diverse health outcomes
during type 2 diabetes, an impact on cognitive decline cannot be
ruled out. Indeed, data regarding a predictive role of fat tissue
distribution on cognitive decline in older persons with type 2
diabetes is lacking.
To address the hypothesis that body fat tissue distribution in
older persons with diabetes may predict a greater decline in
cognitive performance, we examined the relationship between
adiposity parameters at baseline and the risk of decline on
cognitive performance over a two year observation period in a
large group of older persons with DM and NGT.
Results
A total of 221 participants with DM (87%) and 363 with NGT
(83%) completed study protocol(Figure 1).
Baseline data
Study population clinical characteristics are reported in Table 1.
The mean (SD) age of the participants at baseline was 73.6(2.8)
years. Compared with participants with NGT (n=440), those with
DM(n=253) were heavier, had greater central fat distribution,
more elevated IL-6 and FPG levels as well as a higher percentage
of hypertension(Table 1). There were no significant differences
among neuropsychological test scores between groups at baseline.
In those with DM, we also a significant correlation between total
fat mass and HbA1c levels (r=0.2100; p=0.009).
Multivariate linear models testing independent associations among
adiposity parameters (BMI, WHR, WC, Total fat mass), chronic
inflammation(IL-6) and cognitive tests (MMSE, CCS) showed that
MMSE was associated with WHR (b=20.240;p=0.043), WC
(b=20.264;p=0.041) and IL-6 concentrations(b=20.172;p=0.014),
while CCS was associated with WHR(b=20.238;p=0.041),
WC(b=20.326;p=0.013), IL-6 concentrations(b=20.188;p=0.007),
and total fat mass(b=20.272;p=0.033) after adjusting for age, sex and
years of education in DM participants. In NGT participants, no
significant correlations were found among any adiposity parameters and
cognitive test scores on MMSE(data not shown), while CCS was
independently correlated with WHR(b=20.194;p=0.036) and
WC(b=20.210;p=0.024) at baseline.
Participants with DM in the upper tertile of baseline total fat
mass had significantly lower MMSE and CCS scores(Figure 2a–2b)
and significantly higher plasma levels of IL-6 compared to those in
lower tertiles(Figure 2). Such distribution across total fat mass
tertiles was not found in those participants with NGT(Figure 2).
Follow-up data
At the 2
nd year of follow up, DM subjects had gluco-metabolic
parameters comparable to baseline ones (HbA1c (6.660.3 vs.
6.860.2,p=NS) and FPG (8.160.4 vs. 8.460.3 mmol/l), despite
an increase in BMI (27.163.3 vs. 28.463.0;p=0.002),WHR
(0.9160.08 vs. 0.9360.09), Total fat mass (26.068.6 vs.
26.468.9 kg; p=0.028) and WC (91.169.6 vs. 93.260.7 cm;
p=0.002). A worsening degree of cognitive performance on
Figure 1. Figure 1 depicts patient recruitment and follow-up diagram.
doi:10.1371/journal.pone.0010333.g001
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vs. 0.04160.03;p,0.02) was found. In NGT participants, we also
found a significant increase in total body fat (25.766.8 vs.
27.267.2 kg; p=0.023), BMI (26.363.7 vs. 27.263.4 kg/m
2;
p=0.012), WC (89.7611.1 vs. 91.269.8 cm; p,0.001), but
without any significant change in cognitive performance compared
to baseline values (MMSE:26.261.1 vs. 25.961.2;p=NS; CCS
(0.06060.06 vs. 0.05260.03;p=NS).
Over 2 years of follow-up, in DM participants in the 3
rd baseline
tertile of total fat mass had a greater decline in MMSE(p for
trend=0.007) and CCS(p for trend=0.003) than those in the 1
st
tertile. Such trend was also observed in those with NGT, but did
not reach statistical significance on either the MMSE or the CCS.
Logistic regression models were used to test the hypothesis that
the adiposity parameters would be associated with a higher risk of
developing poor cognitive decline(MMSE #24) at the 2
nd year of
follow-up in older persons with DM(Table 2). We found that
baseline WC, WHR and the 3
rd vs. 1
st tertile of total fat mass were
significant risk factors for poor cognitive scoring(Table 2).
In a similar analysis testing the independent relationship
between CCS, as dependent and continuous variable, baseline
adiposity measures such as, WHR, WC and total fat mass values
were independent determinants after adjusting for baseline CCS
and multiple confounders in DM patients(Table 3). Considering
that baseline CCS was also independently associated with WHR
and WC, we performed the same analyses in those with NGT. In
this latter group, no significant correlations among CCS with any
baseline adiposity parameter at the 2
nd year of follow-up were
observed(data not shown).
Discussion
The present study provides evidence that adiposity measures of
total fat mass and central fat distribution are associated with a
decline in cognitive performance in overweight older persons with
DM but not in those with NGT. In particular, we found that older
persons with DM in the 3
rd tertile of total fat mass at baseline were
associated with an approximately two-fold risk of a global
cognitive performance decline after 2 years of follow-up.
Table 1. Population characteristics at baseline (n=693).
Characteristic NGT (n=440) Type 2 Diabetes (n=253) p value
Age, yrs 74667 6 670 . 2 0 3
Gender (M/F)
Education, yrs 5.763.8 6.363.3 0.649
Hypertension (%) 310 (71%) 201 (79%) 0.129
IMT, mm 0.6560.2 0.7360.1* 0.004
SBP (mmHg) 145619 155621 0.020
DBP (mmHg) 88699 2 611 0.105
BMI (kg/m
2) 26.363.7 27.263.3* 0.033
WC (cm) 89.7611.1 91.169.6* 0.046
WHR 0.8960.07 0.9160.08* 0.050
Total cholesterol (mmol/l) 4.160.2 5.260.4 0.004
HDL cholesterol (mmol/l) 1.4260.39 1.2860.10 ,0.001
LDL cholesterol (mmol/l) 2.8060.24 3.1160.31 ,0.001
Triglycerides (mmol/l) 1.3760.83 1.9560.38 ,0.001
Total fat mass (kg) 25.766.8 26.068.6 0.110
FPG (mmol/l) 4.860.4 9.060.4 ,0.001
HbA1c (%) 6.660.3
IL-6 (pmol/l) 2.262.1 2.662.9 0.006
MMSE 26.162.5 25.362.2 0.823
TMT-A, sec 63646 60639 0.794
TMT-B, sec 163671 158693 0.718
DIFFBA, sec 98668 102653 0.626
VF 26.464.2 25.964.8 0.688
DSP-forward 6.861.1 6.661.0 0.721
DSP-backward 5.160.7 4.960.8 0.783
Depression score 12.862.3 13.963.6 0.075
Duration of diabetes, y 9.865.9
Antidiabetic oral agents (%) 78%
Diet only (%) 22%
Note: BMI=body mass index; WC=Waist circumference; WHR=waist-hip-ratio; MMSE=Mini-Mental State Examination; SBP=systolic blood pressure, DBP=diastolic
blood pressure.
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risk was found for global cognitive decline was found. The CCS
score which represents attention and executive functioning,
putative of cerebral frontal lobe functioning was also associated
with the same adiposity parameters, including the 3
rd vs. 1
st tertile
of total fat mass, WC and WHR over time. These above findings
were found independently of age, sex, chronic inflammation,
hypertension, metabolic control and years of formal education.
Data in the literature regarding body fat distribution and
cognition in older persons remains controversial. While, one study
showed that increased central obesity was associated with cognitive
performance decline in women[8] others showed central obesity to
be associated with cognitive decline in both men and women[9].
There is also strong evidence that the relationship between central
adiposity and hypertension may explain lower results on
neuropsychological test scores[12,13]. This synergistic effect of
central adiposity and hypertension may be linked to a greater pro-
inflammatory state, insulin resistance and cardiovascular risk
factors. Indeed our study design excluded older individuals with
severe hypertension and/or coronary heart disease and our data
reveal that both total fat mass and central adiposity were
significantly associated with cognitive decline independently of
the presence of hypertension and intimal media thickness.
The risk of dementia in older persons with DM is significantly
higher than inthosewith NGT[2] and numerous investigations have
been undertaken to determine the underlying mechanisms for such
risk. In particular, recent studies have found an impact of metabolic
control during diabetes including HbA1C, FPG, PPG on cognitive
performance decline in older persons[3–4,14]. Nevertheless whether
a possible role of fat tissue per se and/or body composition may
directly impact cognitive performance in older diabetics is lacking.
Most studies have linked obesity to a higher degree of insulin
resistance which is known to have an important role on cognitive
decline. To the best of our knowledge this study is the first to
highlightthat individualswith DM with higherlevelsoftotalfat mass
and central adiposity distribution are at higher risk for cognitive
decline over time, while such parameters do not seem to have an
impact on cognitive performance in NGT subjects. These findings
indicate that markers of central fat distribution which are widely
known toreflectvisceral fat content can not be underestimated when
evaluating cognitive functioning in older persons with DM,
especially for global, executive and attention functioning. Further-
more, weight gain in middle age is associated with a higher risk for
dementia[15–16]. However, in elderly less than 75 years of age, the
association between Alzheimer’s disease and BMI depicted a U-
shape curve, while the risk for dementia decreased in those with
higher BMI in older persons over the age of 76 years. Interestingly
this same study showed that WC was related to a higher risk of
dementia in all ages[17]. Furthermore, weight change does not seem
to vary significantly in older persons, while tissue fat content is
constantly increasing[18]. Therefore, it is not surprising that we did
not find any association with BMI status and cognitive functioning
considering that aging is characterized by lean body mass loss and
adipose tissue increase without weight gain. An important advantage
of our study was that we used the BIA method to directly assess total
body fat mass and WC for visceral fat, thus overcoming the burden
of using only BMI as an adiposity measure in elderly persons.
A possible explanation of why fat tissue seems to be particularly
detrimental during diabetes is probably linked to the increased
production of pro-inflammatory cytokines[19]. Adipose tissue is an
active endocrine organ which produces adipokines know to have
both pro and anti-inflammatory properties including adiponectin,
leptin, resistin, as well as pro-inflammatory cytokines like tumor
necrosis factor-a and Il-6[20]. Leptin levels have been associated
with cognitive performance in older individuals[21] In regards to
pro-inflammatory cytokines, we found that older persons with DM
had significantly higher levels of IL-6 at baseline than those with
NGT and even after controlling for IL-6 levels, total fat mass, WC
and WHR continued to be risk factors for cognitive decline on
MMSE and CCS. We acknowledge that one of the most important
anti-inflammatory adipokines, adiponectin, was not measured in
these participants and thus an anti-inflammatory role cannot be
ruled out. Even though there is recent data highlighting an anti-
inflammatory mechanism of adiponectin on cerebral vascular
tissue[22], a possible protective action of adiponectin in those with
NGT cannot be underestimated. However, the pro-inflammatory
status during DM and aging seems to have a more damaging effect
on diverse disease states including cognitive decline. Even after
adjusting for chronic inflammation, central obesity and total fat
mass continued to predict cognitive performance decline.
Figure 2. Figure 2 shows MMSE scores, CCS and IL-6 levels
across baseline tertiles of total fat mass in persons with DM
and NGT; (p for trend ,0.05 in DM only for all figures). (black
diamonds: DM; black circles: NGT).
doi:10.1371/journal.pone.0010333.g002
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distribution are independent risk factors for cognitive decline in
older persons with DM, thus implicating that a direct role may be
played by visceral fat tissue on cognitive performance. Future
intervention trials testing if an improvement of such parameters are
necessary to determine their impact on cognition in older diabetics.
Materials and Methods
Ethics Statement
All subjects gave their informed consent before participating in
the study, which the ethical committee of our institution approved.
Study Population
Two hundred and fifty three older persons (age range from 65–
85 yrs) with DM in anti-diabetic oral or diet controlled treatment
and four hundred and forty with NGT volunteered for the study.
Data collection started in September 2002 and was completed in
January 2009(Figure 1).All participants were selected from
university out-patient offices(n=2) after the exclusion of severe
macro- and microangiopathy, coronary heart disease, heart
failure, renal failure, depression, dementia and/or any signs of
edema or dehydration. No subject was using drugs that could
affect water-mineral homeostasis. An oral glucose tolerance
test(75 g glucose) was used to test for DM in those individuals
with fasting glucose levels between 100 mg/dl and 124 mg/dl.
Each participant underwent an in-person interview of general
health and function, including medical history three weeks prior to
study entry with training for the correct use of self blood glucose
monitoring instrument in those with DM. Two weeks prior to the
baseline and follow-up visits, DM participants were asked to
record his/her self-monitoring of blood glucose levels at fasting
and 2 hours after lunch and dinner two times a week. During
visits, DM participants were administered a standard main meal in
accordance with their individual dietary pattern and 2-hour post-
prandial blood samples were drawn and stored for determinations
of plasma metabolites. In all participants, a standard clinical
examination, biochemical parameters, adiposity measurements,
physical and neuropsychological assessments were assessed at
baseline and the 2
ndyr follow-up visit.
Table 2. Odds ratio and 95% confidence intervals for cognitive impairment (MMSE ,24) at follow-up by adiposity measures in
older persons with type 2 diabetes (n=221).
Unadjusted Model 1 Model 2
OR 95% CI p OR 95% CI p OR 95% CI P
BMI (kg/m
2) 0.13 0.76–1.01 0.13 0.29 0.75–1.10 0.29 0.36 0.77–1.10 0.360
WHR* 1.42 1.34–3.11 0.04 1.11 1.01–1.12 0.04 1.13 1.15–2.08 0.050
WC* (cm) 1.81 1.21–3.51 0.03 1.33 1.21–2.89 0.04 1.23 1.09–1.41 0.008
Total fat mass (kg)
Tertile 1 1.00 - - 1.00 - - 1.00 - -
Tertile 2 1.41 0.70–2.78 0.47 1.26 0.65–2.41 0.46 1.17 0.54–2.39 0.64
Tertile 3 2.20 1.23–4.32 0.02 1.92 1.2–3.71 0.04 1.68 1.08–3.52 0.02
Model 1 included the following confounders: age, gender, yrs of education, physical activity, depression.
Model 2=Model 1 + BMI, hypertension, smoking IMT, Hb1Ac, CV-PPG, IL-6, Drug vs. diet
1
1see methods.
*WHR and WC were entered separately in models.
doi:10.1371/journal.pone.0010333.t002
Table 3. Multivariate linear models testing the independent relationship between CCS, as dependent variable, and adiposity
measures according to diabetes status.
Unadjusted Model 1 Model 2
b (SE) p b (SE) p b (SE) p
DM
BMI (kg/m
2) 20.021 (0.023) 0.349 20.021 (0.022) 0.386 20.020 (0.021) 0.394
WHR* 22.741 (1.001) 0.014 22.264 (0.955) 0.042 22.358 (1.065) 0.050
WC* (cm) 20.018 (0.007) 0.009 20.020 (0.010) 0.020 20.019 (0.010) 0.029
Total fat mass
Tertile 1 Ref - Ref - Ref -
Tertile 2 21.771 (1.410) 0.222 20.858 (0.571) 0.370 20.668 (0.546) 0.532
Tertile 3 21.237 (0.329) 0.001 21.085 (0.295) 0.002 20.887 (0.279) 0.004
Model 1 included the following confounders: age, gender, yrs of education, physical activity, depression.
Model 2=Model 1 + BMI, hypertension, smoking IMT, Hb1Ac, CV-PPG, IL-6, Drug vs. diet
1.
1see methods.
*WHR and WC were entered separately in models.
doi:10.1371/journal.pone.0010333.t003
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Weight, height, WC and WHR were measured using standard
techniques. Body mass index(BMI) was calculated as weight(kg)
divided by height(m) squared.
Total fat mass and total fat percentage were calculated using the
Body Composition Analyzer Scale BF-350 (Tanita Corporation)
which uses leg-to-leg bioelectrical impedance analysis(BIA). This
technique provides a valid measure of total body fat in older adults
compared to the traditional hand-to-foot BIA method [23–24].
Neuropsychological battery
All participants underwent the following tests of cognitive
performance: Mini Mental State Examination(MMSE), the Verbal
Fluency(VF), Digit span (DSp) forward and backward, Trail
Making Test A(TMT-A) and Trail Making Test B(TMT-B). All
cognitive evaluations were made by trained physicians who were
unaware of study protocol.
The MMSE was used to assess for global cognitive function[25].
The TMT is visuomotor speeded task that consists of two parts:
TMT-A and TMT-B. TMT-A, visual scanning test, requires one
to draw a line connecting consecutive numbers from 1 to 25.
TMT-B, adds cognitive flexibility to TMT-A and requires one to
draw a line connecting numbers and letters in alternating
sequence. The difference between the two scores, TMT-B minus
TMT-A, provides a measure of cognitive efficiency[26]. Verbal
fluency test require participants to generate as many words as
possible in 1 minute for a given letter (F,A,S)[25].
The Wechsler Adult Intelligence Scale-Revised Digit Span is a
measure of mental tracking as well as, of brief storage and mental
manipulation[25].
Depression was evaluated using the Center for Epidemiological
Studies Depression Scale(CES-D) [27].
Metabolic determinations
Serum glucose, lipid, and lipoprotein were quantified from fresh
samples drawn after a least 12 hours fasting. Serum glucose level
was determined by an enzymatic colorimetric assay using a
modified glucose oxidase-peroxidase method and a Roche-Hitachi
917 analyzer. Commercial enzymatic tests were used for
determining serum total and high-density lipoprotein cholesterol
and triglyceride (Roche Diagnostics, Germany) levels. Serum low-
density lipoprotein cholesterol levels were calculated by the
Friedewald formula [28].
Serum samples for Interleukin 6(IL-6) levels were stored at 280uC
until assay. Serum concentrations of IL-6 were determined in duplicate
manner with commercially available kits(R&D Systems). Intra-assay
and interassay coefficients of variation were 3.9% and 5.9%.
Physical activity
A modified version of the European Prospective Investigation
on Cancer and Nutrition physical activity questionnaire was
performed[29]. The level of physical activity ranged from
1(bedridden) to 7(high intense physical activity).
Other covariates
Smoking habit was categorized according to cigarette use as
current smoker and never smoked. Blood pressure was recorded by
mercury sphygmomanometer on three occasions separated by 2
minute intervalsand the average of the last two measures was used for
analysis. Hypertension was defined according to the following criteria
as: systolic arterial pressure .140 mmHg and diastolic arterial
pressure .90 mmHg and/or taking antihypertensive medication.
Carotid ultrasound evaluation was performed by two trained
investigators who were unaware of study protocol.
In those participants with DM, a dichotomous drug variable
was created in which 1 was equal to the presence of an oral anti-
diabetic oral treatment or 0 equal to diet controlled treatment.
Statistical Analysis
Statistical analyses were performed using SPSS software(Chica-
go,IL). All data arerepresented as mean6standarddeviation(SD).To
approximate normal distributions, log-transformed values for plasma
IL-6 and triglycerides, were used in analyses and back transformed
for data presentation. Analysis of variance(ANOVA) test was used to
evaluate the differences in clinical and metabolic characteristics
between those with DM and NGT and across total body fat tertiles.
Multivariate linear models were created to test the independent
associations among adiposity parameters and cognitive test scores at
baseline after adjusting for age, sex and years of education. Pearson
coefficient correlations were performed to test the association
between Hb1Ac and total fat mass in those with type 2 diabetes.
As previously reported[6], a cluster analysis was created by
using the squared sum of z scores, in order to obtain an overall
value of attention and executive function test. The cognition
composite score of attention and executive functions(CCS) was
calculated as sum of the squared z scores of TMT-A, TMT-B,
DIFF B-A, Dsp-Forward, Dsp- Backward, and VF.
Multivariate linear regressions models were performed at
baseline separately in DM and NGT participants to test the
relationship between cognitive test scores(CCS and MMSE) and
tertiles of total fat mass, total fat mass after adjusting multiple
confounders. For each patient with DM, the levels of mean fasting
plasma glucose(M-FPG), coefficient variation(CV) of fasting
plasma glucose(CV-FPG), and CV of post-prandial glucose(CV-
PPG) were computed[30]. Glucose levels used in the analysis were
those registered by self monitoring blood glucose, as well as those
obtained during the follow-up visit. 24-hour CV were calculated
using two determinations for PPG (2 hour post –lunch and –
dinner glucose levels taken two times a week and the PPG
following the standard meal during the examination. ANOVA
tested the association between the change in cognitive perfor-
mance as dependent variable across tertiles of baseline total fat
mass. Logistic regression models were created and performed
separately according to diabetes to assess the risk of developing
poor cognitive performance(MMSE #24) at follow-up according
to adiposity measures after adjusting for confounders. A
multivariate linear analysis was used with the CCS as dependent
variable to test the independent relationship with diverse adiposity
measures after adjusting for confounders.
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